gsk

ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative DiseasesABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases

ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases

- ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will…

1 month ago
A Total of USD 12.7 Million Investment in New Diagnostics and Drug Development for NTDs and Malaria to Partners Including the Ohio State University, PATH, GSK and OthersA Total of USD 12.7 Million Investment in New Diagnostics and Drug Development for NTDs and Malaria to Partners Including the Ohio State University, PATH, GSK and Others

A Total of USD 12.7 Million Investment in New Diagnostics and Drug Development for NTDs and Malaria to Partners Including the Ohio State University, PATH, GSK and Others

TOKYO, Jan. 30, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 2…

4 months ago